Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer

Yang, Z; Liang, SQ; Saliakoura, M; Yang, HT; Vassella, E; Konstantinidou, G; Tschan, M; Hegedus, B; Zhao, L; Gao, YY; Xu, D; Deng, HB; Marti, TM; Kocher, GJ; Wang, WX; Schmid, RA; Peng, RW

Schmid, RA; Peng, RW (corresponding author), Univ Bern, Bern Univ Hosp, Inselspital, Div Gen Thorac Surg,Dept BioMed Res DBMR, Bern, Switzerland.

EMBO MOLECULAR MEDICINE, 2021; 13 (9):

Abstract

KRAS oncoprotein is commonly mutated in human cancer, but effective therapies specifically targeting KRAS-driven tumors remain elusive. Here, we show ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索